Retrospective application of the VISION trial’s inclusion criteria shows benefits in OS and PFS following PSMA–RLT, but the TheraP criteria may be too stringent for patients with advanced prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.